Payment overview · 2025
General Payments
$196.64
10 reported records · 7 companies
Healthcare provider profile · identity verified
Eric S Bouchard, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TALLAHASSEE, FL · NPI 1295742740
Verified facts
What the public records show
CMS Open Payments records show Eric S Bouchard, MD received $196.64 in general payments during 2025 across 10 reported records.
Agios Pharmaceuticals, Inc. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.18 | 30.6% | 3 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $29.42 | 15.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.25 | 13.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.20 | 13.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.14 | 10.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.03 | 10.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.42 | 6.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $196.64 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $60.18 | 3 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.42 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 607 | 150 |
| Metoprolol Succinate | Metoprolol Succinate | 597 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 525 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 522 | 139 |
| Losartan Potassium | Losartan Potassium | 425 | 109 |
| Ezetimibe | Ezetimibe | 402 | 99 |
| Eliquis | Apixaban | 383 | 67 |
| Omeprazole | Omeprazole | 360 | 100 |
| Lisinopril | Lisinopril | 342 | 91 |
| Furosemide | Furosemide | 251 | 62 |
| Gabapentin | Gabapentin | 251 | 57 |
| Montelukast Sodium | Montelukast Sodium | 250 | 74 |
| Metformin Hcl | Metformin Hcl | 238 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 223 | 63 |
| Jardiance | Empagliflozin | 215 | 45 |
| Prednisone | Prednisone | 180 | 115 |
| Memantine Hcl | Memantine Hcl | 160 | 35 |
| Irbesartan | Irbesartan | 142 | 36 |
| Potassium Chloride | Potassium Chloride | 142 | 43 |
| Atenolol | Atenolol | 137 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 36 |
| Ozempic | Semaglutide | 133 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 125 | 45 |
| Repatha Sureclick | Evolocumab | 125 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 31 |
| Allopurinol | Allopurinol | 121 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 28 |
| Chlorthalidone | Chlorthalidone | 115 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 111 | 22 |
| Sertraline Hcl | Sertraline Hcl | 110 | 27 |
| Lorazepam | Lorazepam | 108 | 25 |
| Spironolactone | Spironolactone | 104 | 30 |
| Carvedilol | Carvedilol | 96 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 33 |
| Torsemide | Torsemide | 96 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 95 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 26 |
| Alprazolam | Alprazolam | 88 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 34 |
| Clonidine Hcl | Clonidine Hcl | 83 | 32 |
| Trazodone Hcl | Trazodone Hcl | 79 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 18 |
| Amoxicillin | Amoxicillin | 73 | 53 |
| Azithromycin | Azithromycin | 70 | 59 |
| Cefuroxime | Cefuroxime Axetil | 70 | 49 |
| Finasteride | Finasteride | 68 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 41 |
| Famotidine | Famotidine | 65 | 24 |
| Celecoxib | Celecoxib | 61 | 13 |
| Valacyclovir | Valacyclovir Hcl | 58 | 22 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 49 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 14 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 12 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 13 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Rybelsus | Semaglutide | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 34 |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 30 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | 12 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 11 |
| Donepezil Hcl | Donepezil Hcl | 36 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 31 |
| Tramadol Hcl | Tramadol Hcl | 36 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | 12 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 20 |
| Estradiol | Estradiol | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 16 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Rivastigmine | Rivastigmine | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 20 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 21 |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Metronidazole | Metronidazole | 22 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $196.64 · 10 records | Agios Pharmaceuticals, Inc. | GEMTESA, LEQVIO, NEFFY, Ozempic, PYRUKYND, QULIPTA, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error